Cargando…

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors

BACKGROUND: Interleukin 17 (IL-17) inhibitors provide an excellent treatment option for patients with psoriasis and psoriatic arthritis, resulting in high levels of efficacy for skin clearance and joint improvement. Safety has also been established in clinical trials for this group of biologic agent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fieldhouse, Keira A, Ukaibe, Samantha, Crowley, Erika L, Khanna, Reena, O’Toole, Ashley, Gooderham, Melinda J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185907/ https://www.ncbi.nlm.nih.gov/pubmed/32362930 http://dx.doi.org/10.7573/dic.2020-2-1

Ejemplares similares

Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections
por: Crowley, Erika L, et al.
Publicado: (2018)

Acrodermatitis continua of Hallopeau successfully treated with adalimumab: A case report
por: Crowley, Erika L, et al.
Publicado: (2019)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors
por: Ward, Madison, et al.
Publicado: (2021)

Return of Lymantria dispar dispar (gypsy moth): A case report
por: Haq, Mawiyah, et al.
Publicado: (2021)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Management of scalp psoriasis: current perspectives
por: Blakely, Kim, et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Diagnosis of Generalized Pustular Psoriasis
por: Fujita, Hideki, et al.
Publicado: (2022)

Interleukin-17 Links Inflammatory Cross-Talks Between Comorbid Psoriasis and Atherosclerosis
por: Wang, Yan, et al.
Publicado: (2022)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis
por: Schön, Michael P., et al.
Publicado: (2018)

Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease
por: Wilke, Cailin M, et al.
Publicado: (2011)

Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study
por: Cai, Yangke, et al.
Publicado: (2023)

Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23
por: Ward, Madison, et al.
Publicado: (2020)

“Role of exercise in preventing and restoring gut dysbiosis in patients with inflammatory bowel disease”: A letter to the editor
por: Mc Gettigan, Neasa, et al.
Publicado: (2022)

Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways
por: Tollenaere, M.A.X., et al.
Publicado: (2021)

Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
por: Menter, Alan, et al.
Publicado: (2021)

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
por: PHAN, Céline, et al.
Publicado: (2020)

Correlations between Psoriasis and Inflammatory Bowel Diseases
por: Skroza, Nevena, et al.
Publicado: (2013)

Psoriasis and inflammatory bowel disease: links and risks
por: Vlachos, Christoforos, et al.
Publicado: (2016)

Psoriasis Features in Patients with Inflammatory Bowel Disease
por: Napolitano, Maddalena, et al.
Publicado: (2019)

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
por: Bolt, Janne W., et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis
por: Truong, Steven L., et al.
Publicado: (2021)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure
por: Griffiths, Christopher E. M., et al.
Publicado: (2022)

An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients
por: Orzan, Olguța Anca, et al.
Publicado: (2023)

Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
por: Cauli, Alberto, et al.
Publicado: (2015)

Gallic acid diminishes pro-inflammatory interferon-γ- and interleukin-17-producing sub-populations in vitro in patients with psoriasis
por: Tsiogkas, Sotirios G., et al.
Publicado: (2023)

34304 Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: Results from the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Interleukin-17 in human inflammatory diseases
por: Shabgah, Arezoo Gowhari, et al.
Publicado: (2014)

Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris
por: Yajima, Makiko, et al.
Publicado: (2019)

Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
por: Sánchez-Dueñas, Luis E., et al.
Publicado: (2020)

The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
por: Egeberg, A., et al.
Publicado: (2020)

Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment
por: Prinz, Immo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_16dq418k8cqbp4h07ke234c4bs